Navigation Links
Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
Date:3/5/2013

tnered programs, the timing of the completion or initiation of further development of our wholly-owned and our partnered programs, expectations that events will occur that will result in greater value for the Company, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our ability to partner our proprietary drug candidates for up-front fees, milestone and/or royalty payments, our future plans to progress and develop our proprietary programs and the plans of our collaborators to progress and develop programs we have licensed to them, and our plans to build a late-stage development company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array BioPharma Inc. to meet objectives tied to milestones and royalties; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the
'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Stem Cell Technology Center, LLC ( ASCTC ) was reported ... research that might benefit ALS patients. Because of ASCTC's ... cell technologies and therapeutic applications, FRC listed ASCTC as one ... donors who wish not to support research that requires the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... on November 2nd and New York on November ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... the,Company will present at three upcoming investor conferences: ... Ghalie, M.D., Chief Medical Officer, will present at ...
... (Nasdaq:,SIAL), a life science company dedicated to providing ... and Oxford,BioMedica (LSE: OXB), a leading gene therapy ... confirming the strength and validity of,intellectual property owned ... field to Sigma-Aldrich. The ruling was part of ...
... to "de-cloak" cancers -, TORONTO, Oct. 25 ... company discovering and developing the next wave of,antibody ... from its Trop-2 and CD59 antibody programs. ARIUS ... at the AACR press,conference today at 9:30 a.m. ...
Cached Biology Technology:Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... Scientists at the University of Warwick have discovered that ... , The substance, methylglyoxal - MG, was found ... of bad cholesterol from the body. , Low ... to heart disease, with increased levels of MG being ... kidney problems. , Supported by funding from the ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2
... carried through the atmosphere before settling on the ocean ... new research from the University of Michigan and the ... Earth Science and Technology (SOEST) combines biogeochemistry and direct ... cycle is colliding with ocean fishand the human seafood ...
... members from The University of Texas at Arlington are ... of Texas System Board of Regents for excellence in ... $25,000 cash award and recognize faculty members at UT ... innovation at the undergraduate level. The professors were recognized ...
... Center Researcher Song-Yi Park, PhD, along with her colleagues, ... vegetables may lower the risk of invasive bladder cancer ... part of the Multiethnic Cohort (MEC) Study, established in ... factors, and cancer risk. Park and her fellow researcher,s ...
Cached Biology News:Ocean fish acquire more mercury at depth 2Ocean fish acquire more mercury at depth 3Ocean fish acquire more mercury at depth 49 UT Arlington educators honored for teaching excellence 2
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Biology Products: